PFE

Pfizer Inc.

New York Stock Exchange

$43.97

Open: $43.29 High: $44.73 Low: $42.92 Close: $43.935

Range: 2021-09-20 - 2021-09-21

Volume:59,875,639

Market: Open

Get Free API Key

Download as Excel

PFE

Pfizer Inc. 235 East 42nd Street New York NY, 10017 http://www.pfizer.com

Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

CEO: Ian C. Read
Employees: 90,200
Sector: Healthcare
Industry: Drug Manufacturers

Latest Stocks Posts

View All Posts >

PFE News

Latest news about the PFE

Restricted Booster Access or Not, BioNTech Stock Is Way Overvalued, Says J.P. Morgan
After a marathon session to determine whether BioNTech (BNTX) and partner Pfizer’s (PFE) Covid-19 booster shot of Comirnaty (BNT162b2) was deserving of approval, the FDA AdCom’s decision was based on a deviation from the intended purpose. The panel concluded that on the original voting question whether all individuals age 16+ should be given a booster shot, there were uncertainties on the safety front (including younger individuals being at risk of myocarditis) and a risk/benefit still unknown f
View More →
Booster shots for those 75+ is a 'no-brainer': Doctor
Dr. Howard Forman, Yale Radiology and Public Health Professor joins Yahoo Finance’s Anjalee Khemlani and the Yahoo Finance Live panel with the latest COVD-19 vaccine update.
View More →
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study. The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma (UC) patients. NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid t
View More →
J&J announces promising COVID-19 booster data, delays on kids' vaccine trial
J&J vaccine data shows lasting durability and strong booster efficacy. However the company has yet to begin trials for a COVID-19 vaccine for children.
View More →
Pfizer's (PFE) COVID-19 Vaccine Successful in Children Study
Pfizer (PFE) and BioNTech's Comirnaty generates non-inferior immune response in children aged 5 to 11 years in pivotal pediatric study compared to the immune response in adults.
View More →
J&J Says Its Booster Shot Works, but Its Vaccine Remains Effective Without a Second Dose
A dose two months after the first shot of its vaccine offered 75% protection against moderate to severe Covid-19 globally, and 94% protection in the U.S.
View More →
Company News for Sep 21, 2021
Companies In The News Are: TSLA, AAL, PFE, BNTX, F.
View More →
India govt won't buy Pfizer, Moderna vaccines amid local output -sources
India's government will not buy COVID-19 shots from Pfizer/BioNTech and Moderna, three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped https://www.reuters.com/world/india/how-india-flipped-its-vaccine-fortunes-2021-09-21. That essentially means the globally popular vaccines, which their makers have pledged not to sell to private parties during the pandemic, will not be available for now in the world's two most populous countries - China and India. No company has received such protection in India.
View More →
J&J says second shot boosts protection for moderate-severe COVID-19 to 94%
Johnson & Johnson said Tuesday a second shot of its COVID-19 vaccine given about two months after the first increased its effectiveness to 94% in the United States against moderate to severe forms of the disease. The data will help J&J make its case to U.S. regulators for a booster shot even as the company stresses the durability of its single-shot vaccine as a tool to ease the global pandemic. President Joe Biden is pushing for booster shots in the face of surging hospitalizations caused by the Delta variant and J&J, the only drugmaker with a single-shot COVID-19 vaccine approved in the United States, has been under pressure to produce evidence on the effectiveness of an additional dose.
View More →
The Smartest Stocks to Buy With $1,000 Right Now
You don't have to invest a massive amount of money to give your portfolio a boost. If you have $1,000 to invest right now, you can snap up shares of companies that have proven themselves through the pandemic -- and will benefit well beyond.
View More →
Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?
A partial victory is better than a complete loss. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are experiencing this firsthand. The two partners had hoped that a U.S. Food and Drug Administration (FDA) advisory committee would recommend COVID-19 vaccine boosters for all Americans ages 16 and up.
View More →
J&J Gains on Claims Its Booster Shot Raises Immunity Against Covid
By Dhirendra Tripathi
View More →
Johnson & Johnson Says Second COVID Vaccine Dose Boosts Overall Efficacy To 94%
"Our large real-world evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations," the drugmaker said.
View More →
Pfizer and BioNTech Say Covid-19 Vaccine Has Positive Results in Children. What to Know.
The study, which tested a smaller dose than is used in the jabs given to people aged 12 and older, found that the vaccine was safe and well-tolerated.
View More →
Pfizer (PFE) Gains As Market Dips: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $44.20, marking a +0.71% move from the previous day.
View More →
America’s kids will be even harder to vaccinate than its adults
Pfizer says its vaccine is safe for kids under 12 but only a quarter of American parents say they will vaccinate their children right away.
View More →
Doctor reacts to U.S. travel ban changes
Baylor College of Medicine Assistant Professor Dr. Sara Andrabi joins Yahoo Finance to discuss the requirement of vaccinations for foreign travelers and other trends amid the COVID-19 pandemic.
View More →
Covid Vaccine Leads To Antibodies In Children — Here's Why BioNTech, Moderna Fell
Pfizer and BioNTech said Monday their Covid vaccine led to a robust antibody response in young children, but the vaccine stocks toppled.
View More →
Why Moderna Stock Is Falling Today
What happened One of the more popular coronavirus stocks, Moderna (NASDAQ: MRNA), was struggling on Monday. Although it wasn't down by as much as the S&P 500 index, Moderna was still off by almost 2% in late afternoon trading.
View More →
3 reasons why the FDA rejected Pfizer's booster shot for general population
The FDA rejected booster shots for the general population, while recommending them for 'high-risk' individuals Monday.
View More →

PFE

PFE

Pfizer Inc. 235 East 42nd Street New York NY, 10017 http://www.pfizer.com

Latest Stocks Posts

View All Posts >

PFE News

Latest news about the PFE

Request a consultation.

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader

PFE

PFE

Pfizer Inc. 235 East 42nd Street New York NY, 10017 http://www.pfizer.com

Share PFE Stock Page

Latest Stocks Posts

View All Posts >

PFE News

Latest news about the PFE

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader